by IR Team | Aug 2, 2022 | Press Releases
Gerald Bagg brings deep understanding of CPG to CUREOXNARD, Calif., Aug. 02, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of...
by IR Team | Aug 1, 2022 | Press Releases
Updates on Recent Transaction and Business will be Provided OXNARD, Calif., Aug. 01, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting a...
by IR Team | Jul 28, 2022 | Press Releases
Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform TechnologyOXNARD, Calif., July 28, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company,...
by IR Team | May 12, 2022 | Press Releases
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD)CCHMC to Seek...
by IR Team | Apr 14, 2022 | Press Releases
LOS ANGELES, April 14, 2022 — Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold at select Walmart Stores, as well as CVS, and Bed Bath & Beyond stores. Sera...
by IR Team | Mar 3, 2022 | Press Releases
COFEPRIS (Mexico’s equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE’s Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE’s patented Oral Thin Film (OTF) dose form...